Vaux David L
Department of Biochemistry, La Trobe University Plenty Road, Bundoora 3086 Victoria Australia.
F1000 Biol Rep. 2009 Oct 29;1:79. doi: 10.3410/B1-79.
Three companies, Genentech, Aegera Therapeutics/Human Genome Sciences, and Novartis, have commenced phase 1 clinical trials of inhibitor of apoptosis (IAP) antagonist 'Smac mimetic' compounds for the treatment of cancer. These trials represent the culmination of a line of research that commenced with analysis of how insect viruses stop host cells from killing themselves and led to the discovery of a family of proteins that regulate development in insects and signalling by tumour necrosis factor superfamily members in mammals, which prompted development of drugs that mimic natural IAP-binding proteins to promote cell death.
基因泰克公司、艾格拉治疗公司/人类基因组科学公司和诺华公司这三家公司已开始针对凋亡抑制蛋白(IAP)拮抗剂“Smac模拟物”化合物开展1期癌症治疗临床试验。这些试验代表了一系列研究的成果,该研究始于对昆虫病毒如何阻止宿主细胞自我死亡的分析,并由此发现了一类调节昆虫发育以及哺乳动物中肿瘤坏死因子超家族成员信号传导的蛋白质家族,这促使研发出模仿天然IAP结合蛋白以促进细胞死亡的药物。